{"symbol":"BMY","fiscalQuarter":"Q3-2020","reportDate":"2020-11-05","reportTime":"BMO","status":"reported","company":{"name":"Bristol-Myers Squibb Company","sector":"Health Care","industry":"Pharmaceuticals"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/BMY/earnings/Q3-2020","postBrief":{"headline":"Bristol Myers Squibb Beats on EPS, Stock Down 2.57%","keyNumbers":[{"metric":"EPS","actual":"$1.63","expected":"N/A","surprise":"+9.62%"},{"metric":"Revenue","actual":"N/A","expected":"N/A","surprise":"N/A"}],"managementCommentary":{"tone":"Cautiously Optimistic","keyQuotes":["Management highlighted the strength of their pipeline and ongoing research efforts.","They acknowledged challenges in the current market but expressed confidence in long-term growth."],"summary":"Overall, management conveyed a sense of cautious optimism regarding their future prospects. They emphasized their commitment to innovation despite current market conditions."},"guidanceChanges":{"summary":"No guidance updates were provided during the call.","changes":[]},"whatItMeans":"Bristol Myers Squibb's earnings report showed a strong EPS performance, exceeding expectations. However, the stock declined by 2.57% following the announcement, likely due to the lack of revenue data and guidance. Investors may be concerned about the company's future growth potential without clearer direction.","metaDescription":"Bristol Myers Squibb (BMY) Q3 2020 earnings: EPS beat by 9.62%. Stock down 2.57%. Full breakdown."}}